Nuvectis Pharma, Inc. SEC Filings

Nuvectis Pharma Chairman and CEO Ron Bentsur bought 12,500 shares of common stock at $20.00 per share in an open-market purchase tied to a public offering announced on June 29, 2026, for a total of $250,000.

After this transaction, he directly owns 3,688,424 shares of Nuvectis Pharma common stock, including shares of restricted common stock.

Nuvectis Pharma, Inc. entered into an underwriting agreement for a firm commitment public offering of 5,000,000 shares of common stock at $20.00 per share, for expected gross proceeds of $100 million. Underwriters also have a 30‑day option to buy up to 750,000 additional shares.

The company expects net proceeds of about $93 million, or approximately $107 million if the underwriters fully exercise the option, after discounts and expenses. The offering is made under Nuvectis’ effective Form S‑3 shelf registration and is expected to close on or about July 1, 2026, subject to customary conditions.

Nuvectis plans to use the net proceeds to advance its pipeline programs NXP100, NXP200, and NXP900, hire additional personnel, fund capital expenditures, cover public company operating costs, and for other general corporate purposes.

Nuvectis Pharma is offering 5,000,000 shares of common stock at $20.00 per share. The offering is expected to raise approximately $100,000,000 before underwriting discounts, with estimated net proceeds to the company of about $93,000,000. The underwriters have an option to purchase an additional 750,000 shares.

Proceeds are intended to fund development of NXP100, NXP200 and NXP900, hiring, capital expenditures and general corporate purposes. The Haisco license agreement tied to NXP100 and NXP200 is subject to certain financing conditions and a required financing milestone.

Nuvectis Pharma, Inc. is offering shares of its common stock under a preliminary prospectus supplement dated June 29, 2026. The offering is a registered primary sale of common stock on Nasdaq (symbol NVCT), with an underwriter option to purchase additional shares for 30 days.

The supplement discloses a June 22, 2026 license agreement with Haisco providing Nuvectis exclusive rights (outside specified Asian territories) to develop, manufacture and commercialize NXP100 and NXP200, subject to financing conditions. Consideration includes a $20 million upfront payment, up to $20 million initial development milestones, up to $1.4 billion contingent milestones and tiered royalties.

Nuvectis Pharma, Inc. reported a change to its existing at-the-market stock sales arrangement with Leerink Partners. The company lowered the amount available for sales under its Sales Agreement prospectus to $5 million, meaning it can offer and sell up to that value of common stock over time.

At the same time, Nuvectis is suspending use of the current Sales Agreement prospectus and will not sell any shares under this arrangement unless and until a new prospectus, prospectus supplement, or registration statement is filed. The underlying Sales Agreement with Leerink Partners remains in full force and effect.

Nuvectis Pharma entered a strategic license agreement with Haisco Pharmaceutical Group for exclusive rights outside China (with certain Asia carve-outs) to two clinical-stage drugs, NXP100 and NXP200. Nuvectis will lead development, manufacturing, and commercialization in its territory, while Haisco continues current work in China.

As consideration, Nuvectis will pay Haisco an upfront $20 million, with up to $20 million in initial development milestones and up to an additional $1.4 billion tied to future development, regulatory, and commercial milestones, plus tiered high-single-digit to mid-teens royalties on net sales. The agreement is subject to financing conditions to ensure Nuvectis has sufficient capital to advance the programs.

NXP100 is a late-stage oral Complement Factor B inhibitor with positive Phase 3 data in paroxysmal nocturnal hemoglobinuria and supportive Phase 2 data in IgA nephropathy, while NXP200 is a brain-penetrant, paradox-breaker BRAF inhibitor with early signals of durable activity across several BRAF-mutated solid tumors.

Hoberman Kenneth reported acquisition or exercise transactions in this Form 4 filing.

Nuvectis Pharma, Inc. director Kenneth Hoberman received a grant of 35,000 shares of restricted common stock. The award was granted at no cash cost per share and is a form of equity compensation rather than an open-market purchase.

The 35,000 restricted shares will vest in equal annual installments over three years, beginning on the first anniversary of the grant date, as long as Hoberman continues serving on the company’s Board of Directors. After this grant, he directly holds 168,140 shares of common stock, which includes restricted shares.

Oliviero James F III reported acquisition or exercise transactions in this Form 4 filing.

Nuvectis Pharma director James F. Oliviero III received a grant of 35,000 shares of restricted common stock. These shares were awarded at no cash cost to him and are part of his equity compensation.

The restricted stock will vest in equal annual installments over three years, starting on the first anniversary of the grant date, as long as he continues serving on the company’s Board of Directors. Following this grant, he holds a total of 122,828 shares of Nuvectis Pharma common stock, including restricted shares.

Sanchez Juan reported acquisition or exercise transactions in this Form 4 filing.

Nuvectis Pharma director Juan Sanchez received a grant of 35,000 shares of restricted common stock at no cost. The award will vest in equal annual installments over three years, starting on the first anniversary of the grant date, as long as he continues serving on the Board of Directors.

After this grant, Sanchez holds 113,380 common shares directly and 415 shares indirectly as custodian for his son. The filing also notes that his current holdings include 230 restricted shares that had been inadvertently omitted from his earlier Form 3.